针叶树皮提取物作为内皮功能调节剂:来自Abies alba和Cedrus brevifolia的证据
Alexandra Barsan Bujor1, Valeriu B Cismasiu2, Sevinci Pop2
1Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Plants (Basel, Switzerland)
|March 14, 2026
概括
来自Abies alba和Cedrus brevifolia的针叶树皮提取物显示出对血管健康的承诺. 这些天然化合物通过增强氧化和减少氧化应激来支持内皮功能.
科学领域:
- 植物化学 植物化学
- 血管生物学 血管生物学
- 内皮细胞功能 内皮细胞功能
背景情况:
- 针叶树皮提取物因其支持内皮健康的潜力而受到关注.
- 内皮功能障碍是各种心血管疾病的关键因素.
研究的目的:
- 为了评估Abies alba和Cedrus brevifolia树皮提取物对血管内皮功能的影响.
- 描述生物活性化合物并评估它们对细胞和生理标记物的影响.
主要方法:
- 液体色谱与高分辨率质谱相结合,用于提取物特性.
- 使用EA.hy926内皮细胞 (活力,增殖,氧化,氧化应激,血管生成) 的体外研究.
- 在实验室中对老鼠大动脉环 (血管松作用) 和酶活性进行研究.
主要成果:
- 阿比斯阿尔巴提取物显示出优异的氧化生产增强,氧化应激减轻和血管生成抑制.
- 这两种提取物都表现出显著的血管松活性,主要由内皮氧化合成酶介导.
- 树叶提取物显示出更大的血管松活性,而阿比斯阿尔巴提取物则具有更强的酶抑制作用.
结论:
- 阿比斯阿尔巴和Cedrus brevifolia树皮提取物都有效地支持内皮功能.
- 这些提取物代表了对心血管健康管理有前途的自然剂.
- 进一步的研究是有必要的,以探索它们的 in vivo 治疗潜力.
关键词:
阿比斯·阿尔巴 (Abies alba) 是一个白色的植物.科德鲁斯大叶 (Cedrus brevifolia) 是一种大叶.在L-NAME中,使用L-NAME.这是LC-HRMS/MS.血管新生是因为血管新生.这是阿尔金纳.针叶树树皮的树皮可以体内的NO生产.通道是的通道.血管放松 血管放松更多相关视频
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Antihypertensive Drugs: Vasodilators
2.4K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
532
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K


